Skip to main content

IP and International Standards

Learning Objectives​

By the end of this chapter, you should be able to:

  • Explain why intellectual property, which is territorial by nature, needs international coordination at all.
  • Identify the major international IP instruments — the Paris Convention, Berne Convention, and TRIPS Agreement — and what each one covers.
  • Describe the role of WIPO and the WTO in administering the global IP system.
  • Explain how the TRIPS Agreement reshaped Indian IP law, especially the shift to product patents in 2005.
  • Discuss the flexibilities TRIPS allows developing countries — compulsory licensing, Section 3(d), and the Doha Declaration — and how India has used them.
  • Analyse landmark cases (Novartis and the Bayer–Natco compulsory licence) that show India balancing treaty obligations against public health.

Quick Answer​

Intellectual property rights are territorial — an Indian patent protects an invention only in India. Because trade, technology, and creative works cross borders, countries built a network of treaties so that IP created in one nation can be respected in others. The three pillars are the Paris Convention (1883) for industrial property, the Berne Convention (1886) for copyright, and the TRIPS Agreement (1994), which is administered by the World Trade Organization (WTO) and sets binding minimum standards for all its members. India, as a WTO member since 1995, amended all its major IP statutes to comply with TRIPS — most dramatically by introducing product patents for medicines in 2005. But TRIPS also leaves "flexibilities" (compulsory licensing, patentability limits, transition periods) that India has actively used to protect access to affordable medicines, most famously through Section 3(d) of the Patents Act and India's first-ever compulsory licence.

Overview​

Imagine a novelist in India whose book becomes a bestseller, only to find it being copied and sold freely in another country with no royalties paid, and no court there willing to help. Or an Indian pharmaceutical firm that develops a process abroad but cannot stop a foreign competitor from using it. This is the fundamental problem of IP: rights granted by one country's law generally stop at that country's border. A patent, trademark, copyright, or design is a national right.

Global commerce made this fragmentation untenable. From the late nineteenth century onward, nations began signing treaties to knit their separate IP systems together — agreeing on shared minimum principles and on ways for a creator in one country to obtain protection in others. The two oldest and most important of these are the Paris Convention (industrial property — patents, trademarks, industrial designs) and the Berne Convention (copyright and related rights). Both are today administered by the World Intellectual Property Organization (WIPO), a specialised agency of the United Nations based in Geneva.

The landscape changed decisively in 1994 with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), negotiated during the Uruguay Round of trade talks and folded into the framework of the newly created World Trade Organization (WTO). Unlike the earlier conventions, TRIPS came with real teeth: a country that fails to meet its IP obligations can be taken to the WTO's Dispute Settlement Body and face trade sanctions. TRIPS did not replace the Paris and Berne Conventions — it incorporated their substantive standards and then added minimum levels of protection and enforcement that every WTO member must guarantee.

For India, joining the WTO in 1995 meant a sweeping overhaul of domestic IP law. The old regime — which, for example, allowed only process patents for pharmaceuticals and food, keeping medicines cheap — had to be brought into line with TRIPS. This chapter traces how India reconciled its treaty commitments with its long-standing public-health and development priorities, using the "flexibilities" that TRIPS itself preserves.

Core Concepts​

Concept 1: Why IP Needs International Standards​

Definition

International IP standards are the shared minimum rules, established through multilateral treaties, that oblige participating countries to protect IP created by nationals of other member countries and to provide certain baseline levels and mechanisms of protection.

Explanation

Two features of IP make international coordination essential:

  1. Territoriality — an IP right exists only under the law that grants it. Without treaties, a creator would have to independently secure and enforce rights, from scratch, in every single country.
  2. The problem of foreign creators — in the nineteenth century, many countries freely copied foreign works and inventions because their own law protected only their own nationals. Treaties fixed this through the principle of national treatment: a member country must give foreign creators from other member countries the same protection it gives its own nationals.

A second guiding principle, added by TRIPS, is most-favoured-nation (MFN) treatment: any advantage a country grants to nationals of one member must be extended to nationals of all members. Together, national treatment and MFN prevent discrimination between domestic and foreign right-holders.

Example

Because both India and France are parties to the Berne Convention, a French author's novel is automatically protected by copyright in India (and vice versa) without any registration formality — India must treat the French author no worse than an Indian author.

Why It Matters

Without these standards, international trade in books, software, films, medicines, branded goods, and technology would be riddled with free-riding. International IP law is what makes it commercially viable to sell creative and innovative products across borders.

Common Misunderstanding

Students often think there is a single "world patent" or "world copyright." There is not. Treaties harmonise standards and ease the process of obtaining protection in multiple countries, but rights are still granted and enforced country by country. Even a patent filed through the international PCT system ultimately becomes a bundle of separate national patents.

Concept 2: The Major International Instruments​

Definition

The international IP framework rests on a small set of foundational treaties, each covering a distinct field, layered under the overarching TRIPS Agreement.

Explanation

  • Paris Convention for the Protection of Industrial Property (1883) — covers patents, trademarks, industrial designs, and unfair competition. Its key contributions are national treatment and the right of priority (a filing in one member country gives you a limited window — 12 months for patents, 6 months for trademarks/designs — to file in other members while keeping your original filing date).
  • Berne Convention for the Protection of Literary and Artistic Works (1886) — covers copyright. It establishes automatic protection (no registration required), national treatment, and minimum protection terms (generally life of the author plus a set number of years).
  • TRIPS Agreement (1994) — the most comprehensive treaty, binding on all WTO members. It incorporates the substantive provisions of the Paris and Berne Conventions, sets minimum standards across patents, copyrights, trademarks, geographical indications, industrial designs, and trade secrets, and — crucially — requires effective enforcement and subjects disputes to the WTO dispute-settlement machinery.
  • The Patent Cooperation Treaty (PCT) and the Madrid System (for trademarks) are procedural treaties administered by WIPO that let applicants seek protection in many countries through a single international application.

Example

An Indian start-up files a patent application in India, then within 12 months files internationally under the PCT claiming the Indian priority date — this uses the Paris Convention priority right operationalised through the PCT to preserve its place in the queue worldwide.

Real-World Example

TRIPS came into force in 1995 alongside the WTO. India, as a founding WTO member, became bound by it and was given transition periods (extended for pharmaceutical product patents until 2005) to bring its laws into compliance — a phased timeline TRIPS specifically allowed for developing countries.

Why It Matters

Knowing which treaty governs which subject matter is a basic exam and practice skill: copyright questions map to Berne, industrial-property questions to Paris, and enforcement or trade-dispute questions to TRIPS/WTO.

Common Misunderstanding

Students frequently confuse WIPO and the WTO. WIPO is a UN agency that administers most IP treaties (Paris, Berne, PCT, Madrid) and promotes cooperation, but it has no power to impose sanctions. The WTO administers TRIPS and can authorise trade sanctions through its dispute-settlement system. TRIPS being under the WTO — not WIPO — is precisely what gave it enforcement power the older conventions lacked.

Concept 3: TRIPS Flexibilities and India's Balancing Act​

Definition

"TRIPS flexibilities" are the lawful policy options built into the TRIPS Agreement that let member countries — especially developing ones — tailor IP protection to their public-health, development, and social needs while remaining compliant.

Explanation

TRIPS sets minimum standards but leaves each country room to decide certain matters. The main flexibilities include:

  1. Defining patentability criteria — TRIPS requires patents for inventions that are new, involve an inventive step, and are industrially applicable, but leaves members to define these terms. India used this to enact Section 3(d) of the Patents Act, which restricts patents on new forms of known substances unless they show enhanced efficacy — a shield against "evergreening" (extending monopolies through minor tweaks).
  2. Compulsory licensing — a country may allow a third party to make a patented product without the patent-holder's consent, under conditions, typically after negotiations fail and on payment of a reasonable royalty. TRIPS permits this (subject to safeguards); the Doha Declaration later clarified members' freedom to use it, especially for public health.
  3. Transition periods — developing and least-developed countries were given extra time to comply.
  4. Parallel imports and exhaustion — members may decide their own rules on importing genuine patented goods sold more cheaply abroad.

The Doha Declaration on the TRIPS Agreement and Public Health (2001) was a landmark WTO ministerial statement affirming that TRIPS "can and should be interpreted and implemented in a manner supportive of WTO members' right to protect public health and, in particular, to promote access to medicines for all." It reassured developing countries that using compulsory licences and other flexibilities was legitimate.

Example

If a life-saving patented drug is priced far beyond what most patients can afford and the patent-holder is not making it reasonably available, a country may grant a compulsory licence allowing a generic manufacturer to produce it at a lower price, paying the patent-holder a royalty.

Real-World Example

In 2012, India's Patent Office granted the country's first compulsory licence to the generic manufacturer Natco Pharma for Bayer's anti-cancer drug sorafenib (Nexavar). The licence was granted on the grounds that the patented drug was not reasonably affordable and not adequately available to the public in India, and it required Natco to pay Bayer a royalty. The decision was upheld on appeal by the Intellectual Property Appellate Board. It became a globally studied example of a developing country using a TRIPS flexibility to advance access to medicines.

Why It Matters

These flexibilities are how India reconciles two goals that can pull in opposite directions: honouring its binding treaty commitments and protecting affordable access to medicines for a vast, largely poor population. Understanding them is central to Indian pharmaceutical patent law.

Common Misunderstanding

Students sometimes think using a compulsory licence or a strict patentability rule violates TRIPS. It does not, when done within the permitted conditions. These are legitimate, TRIPS-compliant tools — the whole point of "flexibilities" is that they operate inside the treaty, not against it.

Case Spotlight: Novartis AG v. Union of India (2013)​

This is the single most important case for understanding how India uses TRIPS flexibilities.

  • What it was about: Novartis sought a patent in India for the beta-crystalline form of imatinib mesylate, marketed as the anti-leukaemia drug Glivec/Gleevec. This was a new form of a substance Novartis had already disclosed earlier.
  • The legal issue: Did this new form clear the bar in Section 3(d) of the Patents Act, 1970, which denies patents to new forms of known substances unless they demonstrate a significant enhancement of therapeutic efficacy?
  • The holding: The Supreme Court of India rejected the patent application, holding that Novartis had not shown the required enhancement in therapeutic efficacy over the known substance. The new form therefore fell foul of Section 3(d).
  • Why it matters: The decision endorsed India's use of a TRIPS flexibility to curb "evergreening" and keep generic versions of essential medicines available and affordable. It confirmed that Section 3(d) sets a genuine, meaningful efficacy threshold, not a mere formality.

Common trap to avoid: Novartis did not "strike down" or challenge the constitutionality of Section 3(d) as a general question in the way sometimes loosely stated. The core of the ruling was that Novartis's specific product did not satisfy the Section 3(d) efficacy test. The case stands for the interpretation and application of Section 3(d), and for India's right under TRIPS to set such patentability standards.

Visual Learning​

The Layers of International IP Law​

How TRIPS Reshaped Indian Patent Law​

Key Terms​

TermDefinitionContext / Related Concepts
TerritorialityThe principle that an IP right exists only under, and within the borders of, the law that grants itThe core reason international treaties are needed
National TreatmentObligation to protect foreign right-holders no worse than one's own nationalsCommon to Paris, Berne, and TRIPS
Most-Favoured-Nation (MFN)Any advantage given to one member's nationals must extend to all members' nationalsIntroduced by TRIPS
Paris Convention (1883)Foundational treaty for industrial property (patents, trademarks, designs)Introduced the right of priority
Berne Convention (1886)Foundational treaty for copyrightAutomatic protection, no registration required
TRIPS Agreement (1994)WTO treaty setting binding minimum IP standards with enforcementIncorporates Paris & Berne standards
WIPOUN specialised agency administering most IP treatiesNo sanctioning power
WTOBody administering TRIPS; hears IP trade disputesCan authorise trade sanctions
Section 3(d), Patents ActBars patents on new forms of known substances lacking enhanced therapeutic efficacyAnti-evergreening tool; central to Novartis
Compulsory LicenceState authorisation for a third party to use a patent without the holder's consent, under conditionsUsed in Bayer–Natco (2012)
Doha Declaration (2001)WTO statement affirming public-health flexibilities within TRIPSReassured members on access to medicines
EvergreeningExtending a monopoly by patenting trivial modifications of a known productWhat Section 3(d) targets

Common Mistakes​

Mistake 1: "WIPO can impose sanctions on countries that break IP treaties." This is wrong. WIPO administers treaties and fosters cooperation but has no enforcement or sanctioning power. It is the WTO, through its Dispute Settlement Body under TRIPS, that can authorise trade sanctions. Confusing the two is a very common error.

Mistake 2: "Using a compulsory licence or Section 3(d) violates TRIPS." This is wrong. Both are TRIPS-compliant flexibilities. TRIPS deliberately leaves members room to define patentability standards and to grant compulsory licences under conditions; the Doha Declaration reaffirmed this for public health. India acts within the treaty, not against it.

Mistake 3: "TRIPS created a single global patent/copyright." This is wrong. There is no world patent or world copyright. TRIPS and the conventions harmonise minimum standards and ease procedures, but rights remain national and are enforced country by country.

Mistake 4: "The Novartis case was about the constitutionality of Section 3(d)." This is a frequent oversimplification. The Supreme Court's ruling turned on whether Novartis's specific new drug form met the therapeutic efficacy requirement of Section 3(d) — it did not. The case is authority on the interpretation and application of that provision, not on striking it down.

Comparison and Connections​

FeatureParis ConventionBerne ConventionTRIPS Agreement
Subject matterIndustrial property (patents, trademarks, designs)Copyright and related rightsAll major IP fields
Year188318861994 (in force 1995)
Administered byWIPOWIPOWTO
Enforcement teethWeak (no sanctions)Weak (no sanctions)Strong (WTO dispute settlement, trade sanctions)
Key principleRight of priority + national treatmentAutomatic protection + national treatmentMinimum standards + national treatment + MFN

This chapter connects to the whole subject: the domestic law on 3. Patents, 2. Copyright, and 4. Trademarks all sits on top of the international standards described here, and 11. Geographical Indications exists in Indian law largely because TRIPS (Articles 22–24) required GI protection. The enforcement mechanisms studied in 8. IP Enforcement reflect the enforcement obligations TRIPS imposes.

Practice Questions​

Recall​

  1. Name the two foundational nineteenth-century IP conventions and the field each covers. Guidance: The Paris Convention (1883) — industrial property (patents, trademarks, designs); the Berne Convention (1886) — copyright.

  2. Which organisation administers TRIPS, and what makes its enforcement stronger than the earlier conventions? Guidance: The WTO administers TRIPS; its Dispute Settlement Body can authorise trade sanctions against non-complying members, giving TRIPS enforcement teeth that Paris and Berne lacked.

Understanding​

  1. Explain the difference in role between WIPO and the WTO in the international IP system. Guidance: WIPO (a UN agency) administers most IP treaties and promotes cooperation but cannot impose sanctions; the WTO administers TRIPS and can authorise trade sanctions through dispute settlement.

  2. What does "national treatment" mean, and why was it historically important? Guidance: A member must protect foreign right-holders from other member states no worse than its own nationals; historically it stopped countries from protecting only their own creators while freely copying foreigners' works.

Application​

  1. An Indian biotech company files a patent application in India and wants to protect the same invention in several other countries. How do international standards help, and what deadline matters? Guidance: Under the Paris Convention right of priority (operationalised via the PCT), the Indian filing date can be preserved for later foreign filings if made within 12 months for patents — letting the company secure its priority worldwide.

  2. A patented anti-cancer drug is sold in India at a price almost no patient can afford, and the patentee is not supplying it adequately. What TRIPS-compliant option does Indian law provide, and which real case illustrates it? Guidance: A compulsory licence may be granted allowing a generic maker to produce the drug on payment of a royalty; India's first, granted to Natco for Bayer's sorafenib (Nexavar) in 2012, illustrates this.

Analysis​

  1. Analyse how India used the flexibilities within TRIPS to protect access to medicines while still complying with the treaty. Guidance: India introduced product patents in 2005 as required but paired them with Section 3(d) (anti-evergreening) and compulsory-licensing provisions, and relied on the Doha Declaration's affirmation of public-health flexibilities — the Novartis ruling and the Bayer–Natco licence show these tools in action.

  2. Evaluate the claim that TRIPS created a "one-size-fits-all" global IP regime. To what extent is this accurate? Guidance: TRIPS sets binding minimum standards and adds strong enforcement, pushing toward harmonisation; but it deliberately preserves flexibilities (defining patentability, compulsory licensing, transition periods, exhaustion rules), so countries retain meaningful policy space — meaning the regime is a harmonised floor, not an identical ceiling.

FAQ​

1. Is IP protection automatic worldwide once I register in India? No. IP rights are territorial. An Indian registration protects you only in India. International treaties make it easier to obtain and defend protection in other member countries, but you must still secure rights in each jurisdiction (except copyright, which is automatic among Berne members).

2. What is the difference between TRIPS and the Paris/Berne Conventions? TRIPS incorporates the substantive standards of Paris and Berne, then adds further minimum standards and, critically, binding enforcement through the WTO. Paris and Berne set standards but have no sanctioning mechanism.

3. Why did India have to change its patent law in 2005? Under its pre-TRIPS regime, India granted only process patents (not product patents) for pharmaceuticals and food, which kept generic medicines cheap. TRIPS required product patents, and after a transition period, the Patents (Amendment) Act, 2005 introduced them — while adding safeguards like Section 3(d).

4. Does using Section 3(d) or a compulsory licence break India's treaty promises? No. Both are lawful flexibilities permitted by TRIPS and reaffirmed for public health by the Doha Declaration. They operate within the treaty framework.

5. What is "evergreening," and how does Indian law address it? Evergreening is extending a patent monopoly by obtaining fresh patents on trivial modifications of a known drug. Section 3(d) addresses it by refusing patents on new forms of known substances unless they show significantly enhanced therapeutic efficacy — the principle applied in the Novartis case.

Quick Revision​

  • IP is territorial — rights are national and enforced country by country; treaties coordinate but do not create a single "world" right.
  • Paris Convention (1883): industrial property; right of priority (12 months for patents). Berne Convention (1886): copyright; automatic protection.
  • TRIPS Agreement (1994, in force 1995): WTO treaty; binding minimum standards across all IP; incorporates Paris & Berne; enforceable via WTO Dispute Settlement.
  • WIPO (UN, Geneva) administers most treaties but cannot sanction; WTO administers TRIPS and can authorise trade sanctions.
  • Core principles: national treatment (Paris, Berne, TRIPS) and most-favoured-nation (TRIPS).
  • India joined the WTO in 1995; introduced product patents for medicines via the Patents (Amendment) Act, 2005.
  • TRIPS flexibilities: defining patentability (Section 3(d)), compulsory licensing, transition periods, exhaustion rules.
  • Doha Declaration (2001): affirmed members' right to use TRIPS flexibilities to protect public health and access to medicines.
  • Novartis AG v. Union of India (2013): Supreme Court refused a patent on a new form of imatinib mesylate (Glivec) for failing Section 3(d)'s enhanced-therapeutic-efficacy test — anti-evergreening.
  • Bayer v. Natco (2012): India's first compulsory licence, for the cancer drug sorafenib (Nexavar), on grounds of affordability and availability.
  • TRIPS Articles 22–24 are why Indian law protects Geographical Indications.

Prerequisites​

Next Topics​